New Delhi, April 17 (IANS) Boosting awareness, early diagnosis, and improving access to care is crucial to fight haemophilia and other bleeding disorders in the country, said Union Minister JP Nadda on World Haemophilia Day on Thursday.
World Haemophilia Day is observed every year on April 17 to raise awareness about bleeding disorders. The theme this year is: “Access for all: Women and Girls Bleed Too”.
Haemophilia is a rare bleeding disorder where blood does not clot properly, even in minor injuries.
“On #WorldHaemophiliaDay, let’s raise awareness about haemophilia and other bleeding disorders, promote early diagnosis, and improve access to care,” said Nadda, in a post on social media platform X.
“This year’s theme — “Access for All: Women and Girls Bleed Too” — urges us to recognise the unique challenges faced by women and girls and ensure inclusive, equitable healthcare for all,” he added.
India faces a significant burden of haemophilia, holding the second-largest patient population globally, estimated at around 1,36,000 individuals.
Yet, “only 18 per cent are diagnosed, compared to 90 per cent in developed nations,” Dr. Tulika Seth, Professor – Haematology, AIIMS Delhi, told IANS.
“Haemophilia is more than a bleeding disorder — it’s a lifelong battle requiring constant care, timely diagnosis, and access to treatment,” she added.
Seth cited the lack of awareness as the major reason for delayed diagnosis, which can lead to preventable joint damage.
Each bleeding episode requires attention, and patients take a prolonged time for recovery and severe complications could occur if any bleeding is not attended.
In about 80 per cent of cases, haemophilia manifests as bleeding, most frequently involving the large joints like knees, ankles, elbows, hip, and wrist, followed by deep bleeds affecting large body muscles.
However, the most dangerous ones are bleeds affecting the head/brain, neck, chest cavity, and abdominal and pelvic cavity.
The expert noted that medical advancements are transforming the lives of patients with the condition.
While traditional treatments involved clotting factor replacement during bleeds, offering prophylaxis or preventive treatment, new non-factor monoclonal replacement antibodies like emicizumab are offering better protection with fewer infusions, especially for patients with inhibitors, Seth said.
Last year, scientists at the Centre for Stem Cell Research (CSCR) at Christian Medical College (CMC), Vellore developed the first-in-human gene therapy using lentiviral vectors for severe haemophilia A.
CMC-Vellore scientists also conducted the country’s first human clinical trial of gene therapy for haemophilia A (FVIII deficiency).
–IANS
rvt/
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by BhaskarLive.in and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of BhaskarLive.in We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, BhaskarLive.in takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
